ALRN 6924-1-05: A Phase 1b Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients with TP53-mutated, HER2 Negative Stage IIa – IIIb Breast Cancer Receiving Neoadjuvant Chemotherapy
This clinical study from Aileron Therapeutics, Inc. is a ‘Supportive Care’ study using an investigational drug called ALRN 6924. The purpose of this study is “To investigate the chemoprotective effects of ALRN-6924 on bone marrow toxicity induced by chemotherapy and identify the dose of ALRN-6924 that will result in optimal reduction of bone marrow toxicity”.
As mentioned above, ALRN 6924 is being tested in its’ ability as a chemoprotective agent; a drug meant to reduce the many blood and bone marrow toxicities associated with chemotherapy, as well as hair loss (alopecia). The idea is to reduce these harsh side effects of chemotherapy in order to make it as tolerable as possible for the patient.
Our dedicated physicians and staff are determined to bring the latest advances in medical research here so you don’t have to go elsewhere for world class medicine.
If you are interested in more information on this study, please contact us at 717-334-4033 Option 7 (Research)